| Human immunodeficiency virus I infection
Delstrigo vs Fuzeon
Side-by-side clinical, coverage, and cost comparison for human immunodeficiency virus i infection.Deep comparison between: Delstrigo vs Fuzeon with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsFuzeon has a higher rate of injection site reactions vs Delstrigo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Fuzeon but not Delstrigo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Delstrigo
Fuzeon
At A Glance
Oral
Once daily
NNRTI/NRTI combination
SC injection
Twice daily
HIV-1 fusion inhibitor
Indications
- Human immunodeficiency virus I infection
- Human immunodeficiency virus I infection
Dosing
Human immunodeficiency virus I infection One tablet orally once daily with or without food in adults and pediatric patients weighing at least 35 kg.
With rifabutin co-administration Take one tablet of DELSTRIGO once daily plus one tablet of doravirine 100 mg (PIFELTRO) approximately 12 hours after the DELSTRIGO dose for the duration of rifabutin co-administration.
Human immunodeficiency virus I infection (Adults) 90 mg (1 mL) SC twice daily injected into the upper arm, anterior thigh, or abdomen.
Human immunodeficiency virus I infection (Pediatric, >=11 kg) 2 mg/kg SC twice daily up to a maximum of 90 mg twice daily injected into the upper arm, anterior thigh, or abdomen; adjust dose with weight changes.
Contraindications
- Co-administration with strong CYP3A inducers, including carbamazepine, oxcarbazepine, phenobarbital, phenytoin, enzalutamide, rifampin, rifapentine, mitotane, or St. John's wort
- Previous hypersensitivity reaction to lamivudine
- Known hypersensitivity to enfuvirtide or any excipient of FUZEON
Adverse Reactions
Most common (>=5%) Dizziness, nausea, abnormal dreams
Serious Severe acute exacerbation of hepatitis B, new onset or worsening renal impairment, bone loss and mineralization defects, immune reconstitution syndrome
Postmarketing Stevens-Johnson syndrome/toxic epidermal necrolysis, hepatitis, lactic acidosis, hepatic steatosis, rhabdomyolysis, acute renal failure, Fanconi syndrome, anaphylaxis, anemia
Most common Local injection site reactions (pain/discomfort, induration, erythema, nodules/cysts, pruritus, ecchymosis), diarrhea, nausea, fatigue, weight decreased, sinusitis, abdominal pain, cough, herpes simplex, appetite decreased, pancreatitis, pneumonia, myalgia
Serious Pneumonia, hypersensitivity reactions, renal failure, Guillain-Barre syndrome, thrombocytopenia, neutropenia, sepsis, toxic hepatitis, unstable angina pectoris
Postmarketing Cutaneous amyloidosis at the injection site
Pharmacology
DELSTRIGO combines doravirine, an NNRTI that non-competitively inhibits HIV-1 reverse transcriptase; lamivudine, a nucleoside analogue NRTI that terminates HIV-1 DNA chain elongation after phosphorylation to lamivudine triphosphate; and tenofovir disoproxil fumarate, a nucleotide analogue prodrug that, following conversion to tenofovir diphosphate, competitively inhibits HIV-1 reverse transcriptase and causes DNA chain termination.
Enfuvirtide is an HIV-1 fusion inhibitor that binds to the first heptad-repeat (HR1) domain of the gp41 subunit of the viral envelope glycoprotein, preventing the conformational changes required for fusion of viral and cellular membranes and thereby blocking HIV-1 entry into CD4+ cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Delstrigo
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (0/12) · Qty limit (11/12)
Fuzeon
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (1/12)
UnitedHealthcare
Delstrigo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (6/8)
Fuzeon
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (2/8) · Qty limit (2/8)
Humana
Delstrigo
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Fuzeon
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Delstrigo or Pifeltro Savings CouponCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
DelstrigoView full Delstrigo profile
FuzeonView full Fuzeon profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.